Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11476835 | 0.84 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL4510419 | 0.82 | ALDH1A1 (0.53) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL8340513 | 0.82 | SLC6A4 (0.47) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL2430164 | 0.80 | HTR2B (0.49) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL473882 | 0.80 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL19534980 | 0.80 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL5975064 | 0.80 | IDO1 (0.55) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL12879014 | 0.80 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL7667135 | 0.80 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL5753110 | 0.80 | ALDH1A1 (0.54) | SLC6A4HTR2AKCNH2APLNRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | claimed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | claimed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | claimed |
| JP-2007511612-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1901916-A | Quinazolinone compounds with reduced in vivo accumulation | CHIRON CORP (US) | 2007-01-24 | — | — | CN | claimed |
| EP-1686996-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | claimed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20100234220-A1 | Oxooxetanes as Fungicidal Agents | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| CN-1901916-A | Quinazolinone compounds with reduced in vivo accumulation | CHIRON CORP (US) | 2007-01-24 | — | — | CN | disclosed |
| EP-1651229-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | Chiron Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| US-4159271-A | CYCLIZATION OF A 2-HALOGENOPHENETHYLAMINE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | SLC6A4 248/4885HTR2A 155/4885KCNH2 1118/4885 |
| US-20100234220-A1 | Oxooxetanes as Fungicidal Agents | CYP51A1, PNPO, AOX1 | SLC6A4 3707/4885HTR2A 4715/4885KCNH2 1671/4885 |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | MC4R, MC5R, MC2R | SLC6A4 177/4885HTR2A 145/4885KCNH2 918/4885 |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | SLC6A4 30/4885HTR2A 112/4885KCNH2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.